Efficacy of liraglutide therapy in Japanese type 2 diabetic patients insufficiently controlled with basal‐supported oral therapy

Journal of Diabetes Investigation

Mitsuyoshi Takahara³  Toshihiko Shiraiwa¹  Kentaro Ohtoshi²  Hideaki Kaneto³  Naoto Katakami³  Taka-aki Matsuoka³ 

[1] Shiraiwa Medical Clinic;Otoshi Medical Clinic, Osaka, Japan;Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Yamadaoka, Suita

关键词: Basal‐supported oral therapy;    Japanese;    Liraglutide;   

DOI  :  10.1111/j.2040-1124.2012.00223.x

来源: Wiley

【 摘 要 】

Abstract

(J Diabetes Invest, doi: 10.1111/j.2040-1124.2012.00223.x, 2012)

Aims/Introduction:  We assessed the efficacy of liraglutide therapy in Japanese type 2 diabetic patients insufficiently controlled with basal-supported oral therapy (BOT).

Materials and Methods:  We retrospectively analyzed the data of 37 patients who had postprandial hyperglycemia (≥10.0 mmol/L) with BOT (long-acting insulin plus glimepiride) with their insulin titrated enough to keep preprandial glycemia <7.2 mmol/L, and who had their treatment changed to liraglutide monotherapy, with the subsequent addition of glimepiride, when required. Those who achieved the glycemic target at all points (preprandial glycemia <7.2 mmol/L and postprandial glycemia <10.0 mmol/L) were regarded as responders and the efficacy of liraglutide therapy was assessed. We also explored the predictive clinical characteristics associated with its efficacy.

Results:  Daily doses of insulin and glimepiride with BOT were 14 ± 9 units and 1.5 ± 0.9 mg, respectively. After the change to liraglutide therapy, 37% of the patients appeared to be responders to the therapy, whereas 12% had their glycemic control rather deteriorated. Efficacy of liraglutide therapy was significantly associated with baseline insulin dosage and post-breakfast glycemia with BOT. The C-statistic of the model was calculated to be 0.90.

Conclusions:  There were responders and non-responders to liraglutide therapy in Japanese BOT failures. It is likely that baseline insulin dosage and post-breakfast glycemia with BOT are clinically useful indicators for the efficacy of liraglutide therapy.

【 授权许可】

Unknown   
© 2012 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd